Healthcare provider profile · identity verified

John Pearson Reed, MD

Family Practice · FISHERSVILLE, VA · NPI 1932361730

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	404	107
Lisinopril	Lisinopril	378	110
Amlodipine Besylate	Amlodipine Besylate	279	86
Metformin Hcl	Metformin Hcl	219	62
Hydrochlorothiazide	Hydrochlorothiazide	193	60
Levothyroxine Sodium	Levothyroxine Sodium	190	50
Simvastatin	Simvastatin	180	41
Omeprazole	Omeprazole	164	41
Losartan Potassium	Losartan Potassium	152	44
Rosuvastatin Calcium	Rosuvastatin Calcium	129	45
Metoprolol Succinate	Metoprolol Succinate	117	35
Furosemide	Furosemide	103	35
Pantoprazole Sodium	Pantoprazole Sodium	101	32
Metoprolol Tartrate	Metoprolol Tartrate	100	23
Tamsulosin Hcl	Tamsulosin Hcl	98	30
Allopurinol	Allopurinol	90	24
Albuterol Sulfate Hfa	Albuterol Sulfate	83	30
Pravastatin Sodium	Pravastatin Sodium	82	24
Eliquis	Apixaban	80	19
Gabapentin	Gabapentin	80	15
Jardiance	Empagliflozin	71	19
Fluticasone Propionate	Fluticasone Propionate	68	18
Lovastatin	Lovastatin	61	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	60	16
Duloxetine Hcl	Duloxetine Hcl	59	14
Famotidine	Famotidine	56	14
Clopidogrel	Clopidogrel Bisulfate	55	17
Trazodone Hcl	Trazodone Hcl	55	13
Carvedilol	Carvedilol	46	14
Montelukast Sodium	Montelukast Sodium	43	13
Atenolol	Atenolol	42	suppressed
Potassium Chloride	Potassium Chloride	40	suppressed
Sertraline Hcl	Sertraline Hcl	39	13
Prednisone	Prednisone	36	27
Metformin Hcl Er	Metformin Hcl	35	11
Valsartan	Valsartan	35	12
Fluoxetine Hcl	Fluoxetine Hcl	33	11
Pioglitazone Hcl	Pioglitazone Hcl	32	suppressed
Januvia	Sitagliptin Phosphate	31	suppressed
Baclofen	Baclofen	30	suppressed
Spironolactone	Spironolactone	28	12
Ezetimibe	Ezetimibe	27	suppressed
Glipizide	Glipizide	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	24	11
Ondansetron Odt	Ondansetron	24	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	19	suppressed
Symbicort	Budesonide/Formoterol Fumarate	19	suppressed
Verapamil Er	Verapamil Hcl	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Ozempic	Semaglutide	18	suppressed
Glipizide Er	Glipizide	17	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Alendronate Sodium	Alendronate Sodium	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Finasteride	Finasteride	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Bumetanide	Bumetanide	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Ibu	Ibuprofen	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error